NCT03700099View on ClinicalTrials.gov

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 3, 2019

Primary Completion Date

March 1, 2024

Study Completion Date

April 1, 2025

Conditions
Prostate CancerCastration-resistant Prostate Cancer
Interventions
DRUG

Docetaxel

Docetaxel 75 mg/m2 IV every 3 weeks, for 6-10 cycles.

DRUG

Enzalutamide

Upon disease progression after treatment with docetaxel, patients will receive Enzalutamide 160 mg P.O. daily until disease progression or limiting toxicity.

Trial Locations (1)

Unknown

Instituto do Câncer do Estado de São Paulo, São Paulo

Sponsors

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

lead

Instituto do Cancer do Estado de São Paulo

OTHER